Blog Post | Thalidomide for Cutaneous Lupus Erythematosus: Which Patients Benefit?
Friday, February 16, 2018
“Clinical benefits must be weighed against potential serious adverse events such as peripheral neuropathy that does not resolve after end of treatment and thromboembolic events.”
Read Full Blog on Dermcast.tv
|
|